The role of MAPK pathway in bone and soft tissue tumors

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 549-553

  Sasaki, Kanji ^a   Hitora, Toshiaki ^a   Nakamura, Osamu ^a   Kono, Ryouta ^a   Yamamoto, Tetsuji ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Malignant fibrous histiocytoma; MAPK signaling pathway; Osteosarcoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALIGNANT FIBROUS HISTIOCYTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; TUMOR CELL LINE;

BLOTTING, WESTERN; BONE NEOPLASMS; BUTADIENES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; NITRILES; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; RNA, MESSENGER;

EID: 79953235832     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Papai Z, Bodoky G, Szanto J, Poller I, Rahoty P, Eckhardt S, Lang I and Szendroi M: The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer 89: 177-180, 2000. (Pubitemid 30451288)
2. Spira AI and Ettinger DS: The use of chemotherapy in soft tissue sarcomas. Oncologist 7: 348-359, 2002. (Pubitemid 34919959)
3. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H and Takahashi T: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296, 1991.
4. Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S and Schutte J: Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 51: 261-265, 2003. (Pubitemid 36469957)
5. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DV and Fidler IJ: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9: 6534-6544, 2003. (Pubitemid 38031842)
6. Arslan MA, Kutuk O and Basaga H: Protein kinases as drug targets in cancer. Curr Cancer Drag Targets 7: 623-634, 2006. (Pubitemid 44691004)
7. Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE and Wasteson A: Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor transforming growth factor-alpha and their receptors. Eur J Cancer 34: 2094-2100, 1998.
8. Yamamoto T, Akisue T, Marui T, Fujita I, Matsumoto K, Kawamoto T, Hitora T, Nakatani T, Nagira K and Kurosaka M: Immunohistochemical analysis of platelet-derived growth factor and its receptors in soft tissue malignant fibrous histiocytoma. Anticancer Res 23: 4325-4328, 2003. (Pubitemid 37474941)
9. Hara H, Akisue T, Fujimoto T, Imabori M, Kawamoto T, Kuroda R, Fujioka H, Yamamoto T, Doita M and Kurosaka M; Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res 26: 4307-4311, 2006. (Pubitemid 46039585)
10. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and Tsubura A: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 127: 7-15, 2001. (Pubitemid 32530087)
11. Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T and Kurosaka M: Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res 27: 423-429, 2007.
12. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR and McCormick F: Ras signaling and therapies. Adv Cancer Res 102: 1-17, 2009.
13. Wang C, Maass T, Krupp M, Thieringer F, Strand S, Wörns MA, Barreiros AP, Galle PR and Teufel A: A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol 50(6): 1122-1131, 2009.
14. Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH and Duesbery NS: Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 7(3): 648-658, 2008. (Pubitemid 351482147)
15. Takayama Y, Kokuryo T, Yokoyama Y, Nagino M, Nimura Y, Senga T and Hamaguchi M: MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett 264(2): 241-249, 2008.
16. Motomura W, Tanno S, Takahashi N, Nagamine M, Fukuda M, Kohgo Y and Okumura T: Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem Biophys Res Commun 332(1): 89-94, 2005. (Pubitemid 40719461)
17. Giehl K, Skripczynski B, Mansard A, Menke A and Gierschik P: Growth factor-dependent activation of the RAS-RAF-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-RAS: implications for cell proliferation and cell migration. Oncogene 19(25): 2930-2942, 2000.
18. Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T and Matsumoto K: Establishment and characterization of cell line TNMY-1 derived from human malignant fibrous histcytoma. Pathol Int 51: 595-602, 2001. (Pubitemid 32947160)
19. Hitora T, Yamomoto T, Akisue T, Marui T, Nakatani T, Kawamoto T, Nagira K, Yoshiya S and Kurosaka M: Establishment and characterization of a KIT-positive and stem cell factor-producing cell line, KTHOS, derived from human osteosarcoma. Pathol Int 55: 41-47, 2005. (Pubitemid 40343722)
20. Fang Z, Mukai H, Nomura K, Shinomiya K, Matsumoto S, Kawaguchi N, Kitagawa T and Kanda H: Establishment and characterization of a cell line from a malignant fibrous histocytoma of bone developing in a patient with multiple fibrous dysplasia. J Cancer Res Clin Oncol 128: 45-49, 2002. (Pubitemid 34151121)
21. Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ and Tang XD: Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway: Cancer Biol Ther 8(18): 1729-1736, 2009.
22. Keswani RN, Chumsangsri A, Mustafi R, Delgado J, Cohen EE and Bissonnette M: Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis Esophagus 21(6): 514-521, 2008.
23. Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G and Milella M: Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 11(8): 720-731, 2009.
24. Leng Q and Mixson AJ: Small interfering RNA targeting inhibits tumor growth in vitro and in vivo. Cancer Gene Therapy 12: 682-690, 2005.
25. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L and Bonavida B: Inhibition of the RAF-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 64: 7117-7126, 2004.
26. Gollob JA, Wilhelm S, Carter C and Kelly SL: Role of RAF kinase in cancer: Therapeutic potential of targeting the RAF/MEK/ERK signal transduction pathway. Sem Oncol 33(4): 392-406, 2006. (Pubitemid 44142735)
27. Benini S, Manara MC, Cerisano V, Perdichizzi S, Serra M, Picci P and Scotlandi K: Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells. Therapeutic prospects. Int J Cancer 108: 358-366, 2004. (Pubitemid 37549600)
28. Messersmith WA, Hidalgo M, Carducci M and Eckhardt SG: Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol 4(11): 831-836, 2006. (Pubitemid 44883551)